JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.5 0.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.49

Max

21.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.93% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.41
Ankstesnė uždarymo kaina	21.5

Naujienos nuotaikos

By Acuity

50%

179 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 00:00; UTC

Svarbiausios naujienos

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026-04-22 23:33; UTC

Uždarbis

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026-04-22 22:40; UTC

Uždarbis

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026-04-22 22:10; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:11; UTC

Uždarbis

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026-04-22 21:01; UTC

Uždarbis

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026-04-22 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026-04-22 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026-04-22 23:16; UTC

Uždarbis

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026-04-22 23:15; UTC

Uždarbis

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026-04-22 22:52; UTC

Uždarbis

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026-04-22 22:51; UTC

Uždarbis

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026-04-22 22:30; UTC

Uždarbis

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026-04-22 22:30; UTC

Uždarbis

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026-04-22 22:29; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026-04-22 22:27; UTC

Uždarbis

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026-04-22 22:06; UTC

Rinkos pokalbiai

Uždarbis

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026-04-22 21:55; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:47; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:37; UTC

Uždarbis

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026-04-22 21:34; UTC

Uždarbis

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026-04-22 21:29; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:20; UTC

Rinkos pokalbiai

Uždarbis

Tesla Expands Manufacturing to Chips -- Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.93% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -2.93%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

179 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.